The Nathan S. Kline Institute for Psychiatric Research

What The Nathan S. Kline Institute for Psychiatric Research does

The Nathan S. Kline Institute for Psychiatric Research (NKI), founded in 1960 in Orangeburg, New York, is a non-profit psychiatric and neuroscience research institute operated as part of the New York State Office of Mental Health system under the Research Foundation for Mental Hygiene, Inc. NKI employs 300+ scientists and staff conducting 120+ active research studies and clinical trials across eight specialized centers and divisions: the Center for Biomedical Imaging and Neuromodulation (C-BIN), Center for Dementia Research (CDR), Clinical Research Division, Emotional Brain Institute (EBI), Geriatric Psychiatry, Information Sciences, Schizophrenia Research, and Social Solutions and Services Research. Focus areas span Alzheimer's disease and related dementias, schizophrenia, mood disorders (depression, bipolar), ADHD, autism, addiction, fear/emotional processing, and health equity. NKI investigators serve as primary research arm for NYU Grossman School of Medicine's Department of Psychiatry, with joint appointments at Columbia University and Cornell, and rank among the world's most-cited researchers (Clarivate Highly Cited Researchers list in 2019, 2023, 2024).

NKI's core technology platforms include ultra-high-field neuroimaging (a 9.4 Tesla MRI in development with Columbia, NYU, Cornell engineering, and GE Global Research), transcranial neuromodulation devices (photobiomodulation, tDCS/tACS, TMS), EEG/quantitative EEG, MR spectroscopy, and molecular biology capabilities (autophagy, endosomal-lysosomal biology, protein biochemistry, animal models). Proprietary software tools include ART (image registration), Kaiba (hippocampal measurement), Yuki (corpus callosum segmentation), PEER (fMRI eye-tracking), the Levy Laboratory's extracellular vesicle and mitovesicle isolation method, and a library of machine-learning classifiers for automated schizophrenia (98% accuracy) and Alzheimer's prediction. The institute also operates and co-founded the International Neuroimaging Data-sharing Initiative (INDI) and the NKI Rockland Sample open multimodal dataset (community lifespan sample ages 6-85), positioning it as a global infrastructure node for open neuroimaging data.

NKI has no commercial revenue streams. Its financial model is built on competitive federal grant funding (NIMH, NIA, NINDS, NIDA, NICHD, NSF — including multi-year P50 Conte Center grants, R01s, P01s, MERIT awards, Javits awards, and SBIR/STTRs), operational support from the New York State Office of Mental Health via the Research Foundation for Mental Hygiene, and restricted/private foundation funding (Brain & Behavior Research Foundation, Alzheimer's Association, CHDI Foundation, Oskar Fischer Prize, New Vision Research) plus pharmaceutical collaborations (Axsome Therapeutics, EIP Pharma). Customer segments are research participants (patients with psychiatric and neurological disorders and healthy volunteers recruited through the Participate in Research program and Clinical Evaluation Center) and the global scientific and medical research community accessing NKI's open datasets, methodologies, and publications.

Name

The Nathan S. Kline Institute for Psychiatric Research

Legal name

The Nathan S. Kline Institute for Psychiatric Research - Research Foundation for Mental Hygiene, Inc.

Website

https://nki.rfmh.org

Company type

Private

Founded year

1960

Operating status

Operating

Short description

The Nathan S. Kline Institute for Psychiatric Research (NKI) is a NY State-affiliated nonprofit psychiatric research institute founded in 1960, employing 300+ scientists conducting 120+ active studies across eight research centers focused on brain imaging, dementia, schizophrenia, mood disorders, and translational neuroscience.

Ownership category

akta.pro rank

Product category

Psychiatric and Neuroscience Research

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Health Services (8000)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Psychiatry & Medication Management Platforms (HLALAEAB), Epilepsy & Seizure Disorders (HLAKAIAB)

Keywords

• Psychiatric research
• Neuroimaging technologies
• Clinical trials
• Dementia research
• Translational neuroscience

Headquarters

HQ city

Orangeburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Federal Research Grant Funding: The primary revenue stream is competitive grant funding from U.S. federal agencies including the National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), and the National Science Foundation (NSF). Major grants include Silvio O. Conte Centers P50 grants, NIH R01 grants, Program Project grants (P01), MERIT awards, Javits Neuroscience Investigator Awards, and SBIR/STTR grants.
2. State of New York Funding: NKI is operated under the New York State Office of Mental Health. The institute receives operational funding from the state, including support from New York State's Research Foundation for Mental Hygiene (RFMH) and the NYS Office of Mental Health for clinical laboratory operations and infrastructure.
3. Private Foundation and Corporate Research Funding: Funding from private foundations including the Brain & Behavior Research Foundation (BBRF/NARSAD), Alzheimer's Association, Oskar Fischer Prize, CHDI Foundation, New Vision Research (Leonard Litwin Scholar Award), and pharmaceutical/biotech company collaborations (e.g., Axsome Therapeutics, EIP Pharma).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

NKI is a non-profit psychiatric and neuroscience research institute that conducts basic, translational, and clinical research on psychiatric and neurodegenerative disorders including schizophrenia, depression, Alzheimer's disease, ADHD, autism, and addiction. Its core offerings include operation of specialized research centers and programs (C-BIN, CDR, Clinical Research, EBI, Geriatric Psychiatry, Information Sciences, Schizophrenia Research, Social Solutions), open neuroimaging data resources (INDI, NKI Rockland Sample), and a portfolio of clinical trials evaluating pharmacological, neuromodulation, and behavioral interventions.

Product overview

The Nathan S. Kline Institute for Psychiatric Research is a clinical research institution operating eight specialized research centers and programs encompassing brain imaging and neuromodulation (C-BIN), dementia research (CDR), clinical research, emotional brain studies (EBI), geriatric psychiatry, information sciences, schizophrenia research, and social solutions research. The institute generates research resources including the NKI Rockland Sample multimodal dataset and hosts the International Neuroimaging Data-sharing Initiative (INDI). It conducts clinical trials including transcranial photobiomodulation studies for Alzheimer's disease and depression. The C-BIN is developing a 9.4T ultra-high field MRI system for human brain research.

Differentiator

Problem solved

Functional benefit

Brands

• Center for Biomedical Imaging and Neuromodulation (C-BIN): Center focused on biomedical imaging and neuromodulation research
• Center for Dementia Research (CDR)
• Emotional Brain Institute (EBI)
• Clinical Research Division

Products and services

• Center for Biomedical Imaging and Neuromodulation (C-BIN) A specialized research center developing and operating ultra-high-field MRI technology (including the 9.4T neuroimaging system), brain stimulation techniques (tDCS, tACS, TMS), and neuroimaging data analysis methodologies for studying human brain function and dysfunction. Designed for neuroscience researchers and clinical collaborators.
• Center for Dementia Research (CDR) Research center focused on the biology of protein clearance, endosomal-lysosomal system dysfunction, autophagy, and axonal transport in Alzheimer's disease and related neurodegenerative disorders. Targets basic and translational dementia researchers.
• Clinical Research Division Clinical research programs investigating mood disorders, depression treatments, transcranial photobiomodulation, cognitive deficits, and pharmacological treatments including ketamine and novel drug therapies. Serves clinical trial sponsors and patients with treatment-resistant psychiatric conditions.
• Emotional Brain Institute (EBI) Research center led by Joseph LeDoux focused on understanding emotional processing, fear conditioning, and the neurobiology of emotional responses. Targets basic and translational neuroscience researchers.
• Geriatric Psychiatry Program Research program focused on psychiatric disorders in older adults, including dementia, cognitive decline, and sleep disorders in aging populations. Supports research on healthy and pathological aging.
• Information Sciences Division Neuroinformatics and data science division supporting neuroimaging data sharing initiatives including the NKI Rockland Sample and International Neuroimaging Data-sharing Initiative (INDI). Serves global neuroimaging researchers.
• Schizophrenia Research Program Comprehensive research program studying schizophrenia neurobiology, including impulsivity, suicidality, aggression, perception deficits, and novel pharmacological treatments. Supports investigators and clinical trial teams in schizophrenia research.
• Social Solutions and Services Research Division Research division addressing social determinants of health, racial disparities, community-based interventions, and behavioral health equity. Supports researchers, community organizations, and policymakers addressing health equity.
• NKI Rockland Sample An open multimodal dataset of brain, physiology, and behavior data from a community lifespan sample (ages 6-85), supporting biomarker discovery and connectome development studies. Free resource for the global scientific community.
• International Neuroimaging Data-sharing Initiative (INDI) Open data sharing initiative co-founded by NKI that aggregates large-scale neuroimaging datasets from laboratories worldwide, including the ADHD 200, Autism Brain Imaging Data Exchange (ABIDE), and Consortium for Reliability and Reproducibility (CoRR) consortia. Provides open data access to the global neuroimaging research community.
• Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) Study Experimental clinical trial investigating near-infrared light therapy (transcranial photobiomodulation) for mild cognitive impairment and Alzheimer's disease, part of the Mood Disorders research program. For research participants with mild cognitive impairment or Alzheimer's disease.
• Transcranial Near-Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE) Study Clinical trial studying near-infrared radiation effects on cerebral blood flow in depression patients using transcranial photobiomodulation techniques. For research participants with depression.

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered core, flagship and notable.

• NYU Grossman School of MedicinecoreStrategic or Co-development PartnerNKI maintains a deep institutional affiliation with NYU Grossman School of Medicine. Multiple NKI investigators hold joint appointments at NYU, including Ralph Nixon (Professor of Psychiatry and Cell Biology), Dan Iosifescu (Professor of Psychiatry), Helen Scharfman (Professor of Child & Adolescent Psychiatry, Psychiatry, and Physiology & Neuroscience), F. Xavier Castellanos (endowed Professor of Child & Adolescent Psychiatry and Professor of Radiology and Neuroscience), and others. NKI serves as the primary research arm for NYU's Department of Psychiatry.
• Columbia UniversitycoreStrategic or Co-development PartnerColumbia University is a key collaborator in multiple NKI initiatives including the 9.4T MRI development project and the Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The Conte Center grant is led jointly by NKI (Charles Schroeder, Michael Milham) and Columbia. Columbia's engineering schools contribute to the 9.4T MRI development.
• Cornell UniversityflagshipTechnology or IntegrationCornell University engineering schools collaborate with NKI on the development of the 9.4T ultra-high-field MRI system, contributing engineering expertise to the ultra-high-field neuroimaging platform.
• GE Global ResearchflagshipTechnology or IntegrationGE Global Research is collaborating with NKI on the development and implementation of the 9.4 Tesla MRI scanner, one of the most powerful imaging systems in the world for neuroscience research.
• Child Mind InstitutecoreStrategic or Co-development PartnerMichael Milham serves as Vice President of Research at the Child Mind Institute while directing C-BIN at NKI, creating a strategic collaboration that bridges NKI's neuroimaging capabilities with the Child Mind Institute's clinical and educational research mission.
• New York State Office of Mental Health (OMH)coreStrategic or Co-development PartnerNKI is a program of the New York State Office of Mental Health. The OMH Clinical Laboratories at NKI are CAP-accredited and serve as a key component of the state's mental health research infrastructure. Funding from OMH supports the 9.4T MRI project and general operations.
• Research Foundation for Mental Hygiene (RFMH)coreOthersNKI operates under the Research Foundation for Mental Hygiene, Inc., a nonprofit research foundation that serves as the institutional employer and grant-receiving entity for NKI's federal and private research funding.
• Axsome TherapeuticsnotableStrategic or Co-development PartnerAxsome Therapeutics collaborated with NKI on a phase 2 clinical trial of AXS-05 (dextromethorphan-bupropion) for major depressive disorder, published in The American Journal of Psychiatry. Dan Iosifescu served as senior author.
• EIP PharmanotableStrategic or Co-development PartnerEIP Pharma worked with Ralph Nixon's lab on research involving neflamapimod (a p38α kinase inhibitor) for Alzheimer's disease, including findings presented at the Alzheimer's Association International Conference and a Nature Communications paper on preclinical and randomized clinical evaluation.
• Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health ResearchflagshipStrategic or Co-development PartnerNKI's Charles Schroeder and Michael Milham received a five-year P50 Conte Center grant renewal titled 'Neurobiology and Cognitive Role of Slow Brain Network Fluctuations.' The Conte Center is a collaborative effort with Columbia University investigating slow brain network fluctuations underlying cognition and behavior.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Janelia Research Campus (HHMI): HHMI's discovery-oriented neuroscience research campus focused on imaging technology, computational neuroscience, and methodological tool development. Highly comparable on technology-development orientation and tool-building approach (e.g., ART/Kaiba/Yuki equivalents at Janelia).
• McGovern Institute for Brain Research (MIT): MIT-based interdisciplinary brain research institute with comparable bench-to-clinic neuroimaging and psychiatric/neurological disease programs, including ultrahigh-field MRI. Overlaps with NKI on circuit-level psychiatry research and elite investigator base.
• Allen Institute for Brain Science: Large-scale, open-data neuroscience research organization that, like NKI, combines proprietary imaging technology, large multimodal datasets, and a community-research-participant model. Highly comparable on data-sharing ethos and translational imaging focus.
• Max Planck Florida Institute for Neuroscience: Non-profit basic neuroscience research institute using advanced imaging (including high-field microscopy) and circuit-level approaches. Closely comparable on technology-development orientation and small elite investigator model.
• Lieber Institute for Brain Development: Non-profit research institute focused on neurodevelopmental and psychiatric disorders using genomics, imaging, and postmortem brain tissue. Direct overlap with NKI in translational psychiatric research methodology and federal-grant funding model.

Broad incumbents

• Wu Tsai Neurosciences Institute (Stanford): Stanford's interdisciplinary neuroscience institute combining imaging, circuit research, and translational psychiatry. Comparable to NKI on the integration of human neuroimaging with psychiatric disease research, though embedded in a much larger private university setting.
• Salk Institute for Biological Studies: Non-profit basic biomedical research organization with deep federal grant funding, ~$850M endowment, and investigator-driven programs spanning neurodegeneration. Comparable in non-profit grant-funded research model but broader than NKI's psychiatric focus.
• National Institute of Mental Health (Intramural Research Program): Federal intramural research program covering the full translational spectrum for mental health — directly comparable to NKI's mission, clinical evaluation services, and grant-funded model. Many NKI investigators hold joint appointments with NIMH-funded academic partners.
• Howard Hughes Medical Institute (HHMI): Major biomedical research organization supporting investigator-led science across many institutions, including neuroscience and imaging modalities. Overlaps with NKI on investigator-driven research and tool/dataset dissemination models.

Emerging players

• Stanley Center for Psychiatric Research (Broad Institute): Large-scale psychiatric genomics and therapeutic discovery initiative embedded in the Broad Institute. Comparable to NKI on psychiatric disease focus but distinct in emphasizing genomics and large-scale computational biology over neuroimaging.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/research-foundation-for-mental-hygiene-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Nathan S. Kline Institute for Psychiatric Research